As 2024 draws to a close, the question on everyone’s mind is — What’s next for medical affairs in 2025? With the healthcare landscape changing at an unprecedented pace, staying ahead means understanding the trends that will define the year ahead. From digital transformation to patient-centric strategies, these shifts are already reshaping the way medical affairs teams operate. Here’s what you need to know to stay prepared and relevant.
In PMC's first breakfast briefing of 2024, PharmaMedic's Managing Director, Dr Malcolm Barratt-Johnson was joined by guest speaker Dr Christine Grew, Director of Regulatory Affairs at Canopy Life Sciences to discuss machine learning and artificial intelligence, and a discussion on how this technology may impact our day-to-day roles.
Our next meeting on Wednesday, 24th April, 2024 will discuss machine learning and artificial intelligence and a discussion on how this technology may impact our day-to-day roles. Join Dr Malcolm Barratt-Johnson, Managing Director of PharmaMedic Consultancy and our guest speaker Dr Christine Grew, Director of Regulatory Affairs at Canopy Life Sciences.
A report by the Association of the British Pharmaceutical Industry (ABPI) shows an ongoing need for AI, digital and data talent to support innovative drug discovery and development. The report, ‘Evolution of an innovation-based biopharmaceutical industry’, published on 8 June 2023, is updated every two years and investigates the latest trends and skills requirements for the life sciences industry in the UK.
Cancer diagnosis and treatment are set to be accelerated with the opening of England’s first Integrated Pathology Unit (IPU). The new facility will apply pioneering digital imaging and artificial intelligence to pathology, assisting clinical trial research programmes focused on developing tests for cancer.
What is the future for UK-based biotechnology? This article reviews the financing of, and governmental support for, the sector and considers the potential impact of new technology in the development of the life sciences.
As part of its plan to make the UK a science and technology superpower by 2030, the government launched its ‘Science and Technology Framework’ on 6 March 2023.
PMC reviews insights from the 41st JP Morgan Healthcare conference, focusing on some of the new treatments and technologies to watch out for in the pharma industry this year – and highlighting challenges to progress.
Pharmacovigilance (PV) – the proactive maintenance of drug safety through collection, detection, assessment, monitoring and prevention of adverse effects – has been evolving since the first concerns were raised over the negative effects of chloroform anaesthetic in the 1800s. Today, it is just as important that pharma, start-ups and regulators keep up to date with the latest trends to ensure that drugs are safe and monitoring practices remain fit for purpose.
With the COVID-19 pandemic disrupting medical provision across the globe, healthcare providers urgently need to improve efficiency of patient care. Read our new article to learn how artificial intelligence is being used in clinical decision-making.
